Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution

Molecular Pharmaceutics

Volumn 5, Issue 4, 2008, Pages 487-495

  Dobrovolskaia, Marina A ^a   Aggarwal, Parag ^a   Hall, Jennifer B ^a   McNeil, Scott E ^a  

^a SAIC FREDERICK INC   (United States)

Author keywords

Biodistribution; Immunology; Nanoparticles; Preclinical characterization

Indexed keywords

NANOPARTICLE; OPSONIN; PLASMA PROTEIN;

COMPLEMENT ACTIVATION; COMPLEX FORMATION; CONFERENCE PAPER; DENDRITIC CELL; DRUG DELIVERY SYSTEM; DRUG UPTAKE; HEMOLYSIS; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IN VITRO STUDY; INTERNALIZATION; LEUKOCYTE; MONOCYTE; PARTICLE SIZE; PHAGOCYTE; PRIORITY JOURNAL; PROTEIN BINDING; SURFACE CHARGE; THROMBOCYTE; THROMBOGENICITY; TISSUE DISTRIBUTION;

DRUG EVALUATION, PRECLINICAL; HUMANS; IMMUNE SYSTEM; MACROPHAGES; NANOMEDICINE; NANOPARTICLES; TISSUE DISTRIBUTION;

EID: 51049108389     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp800032f     Document Type: Conference Paper

References (52)

1. Powers, M. 2006 Nanomedicine, Device & Diagnostics Report. Nanomedicine and nano device pipeline surges 68%. NanoBiotech News 2006, 1-69.
2. Dobrovolskaia, M. A.; McNeil, S. E. Immunological Properties of engineered nanomaterials. Nat. Nanotechnol. 2007, 2 (8), 469-478.
3. Cohen, J. J. Apoptosis: the physiologic pathway of cell death. Hosp. Pract. (Off. Ed.) 1993, 28 (12), 35-43.
4. Schaer, D. J.; Alayash, A. I.; Buehler, P. W. Gating the radical hemoglobin to macrophages: the anti-inflammatory role of CD163, a scavenger receptor. Antioxid. Redox Signaling 2007 9 (7), 991-999.
5. Schroit, A. J.; Madsen, J. W.; Tanaka, Y. In vivo recognition and clearance of red blood cells containing phosphatidylserine in their plasma membranes. J. Biol. Chem. 1985, 260 (8), 5131-5138.
6. Movat, H. Z.; Weiser, W. J.; Glynn, M. F.; Mustard, J. F. Platelet phagocytosis and aggregation. J. Cell Biol. 1965, 27 (3), 531-543.
7. http://astm.org/cgi-bin/SoftCart.exe/COMMIT/COMMITTEE/ E56.htm?L+mystore+vdgw9357.
8. http://es.epa.gov/ncer/nano/.
9. http://icon.rice.edu/.
10. http://www.cdc.gov/niosh/topics/nanotech/default.html.
11. http://www.fda.gov/nanotechnology/.
12. http://www.iso.org/iso/isoťalogue/catalogue_tc/ catalogue_detail.htm?csnumber=45640.
13. Standard Practice for selecting generic biological test methods for materials and devices. ASTM International: 1998; F748-98.
14. ANSI/AAMI/ISO, 10993-4: Biological Evaluation of Medical Devices. Part 4: Selection of Tests for Interaction with Blood; 2002.
15. Domanski, D. M.; Klajnert, B.; Bryszewska, M. Influence of PAMAM dendrimers on human red blood cells. Bioelectrochemistry 2004, 63 (1-2), 189-191.
16. Bermejo, J. F.; Ortega, P.; Chonco, L.; Eritja, R.; Samaniego, R.; Mullner, M.; de Jesus, E.; de la Mata, F. J.; Flores, J. C.; Gomez, R.; Munoz-Fernandez, A. Water-soluble carbosilane dendrimers: synthesis biocompatibility and complexation with oligonucleotides; evaluation for medical applications. Chemistry 2007, 13 (2), 483-495.
17. Agashe, H. B.; Dutta, T.; Garg, M.; Jain, N. K. Investigations on the toxicological profile of functionalized fifth-generation poly (propylene imine) dendrimer. J. Pharm. Pharmacol. 2006, 58 (11), 1491-1498.
18. Dutta, T.; Agashe, H. B.; Garg, M.; Balakrishnan, P.; Kabra, M.; Jain, N. K. Poly (propyleneimine) dendrimer based nanocontainers for targeting of efavirenz to human monocytes/macrophages in vitro. J. Drug Targeting 2007, 15(1), 89-98.
19. Malik, N.; Wiwattanapatapee, R.; Klopsch, R.; Lorenz, K.; Frey, H.; Weener, J. W.; Meijer, E. W.; Paulus, W.; Duncan, R. Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 1251-labelled polyamidoamine dendrimers in vivo. J. Controlled Release 2000, 65 (1-2), 133-148.
20. Shah, D. S.; Sakthivel, T.; Toth, I.; Florence, A. T.; Wilderspin, A. F. DNA transfection and transfected cell viability using amphipathic asymmetric dendrimers. Int. J. Pharm. 2000, 208 (1-2), 41-48.
21. Bosi, S.; Feruglio, L.; Da Ros, T.; Spalluto, G.; Gregoretti, B.; Terdoslavich, M.; Decorti, G.; Passamonti, S.; Moro, S.; Prato, M. Hemolytic effects of water-soluble fullerene derivatives. J. Med. Chem. 2004, 47 (27), 6711-6715.
22. Kim, D.; El-Shall, H.; Dennis, D.; Morey, T. Interaction of PLGA nanoparticles with human blood constituents. Colloids Surf., B: Biointerfaces 2005, 40 (2), 83-91.
23. Kim, T. H.; Nah, J. W.; Cho, M. H.; Park, T. G.; Cho, C. S. Receptor-mediated gene delivery into antigen presenting cells using mannosylated chitosan/DNA nanoparticles. J. Nanosci. Nanotechnol. 2006, 6 (9-10), 2796-2803.
24. Koziara, J. M.; Oh, J. J.; Akers, W. S.; Ferraris, S. P.; Mumper, R. J. Blood compatibility of cetyl alcohol/polysorbate-based nanoparticles. Pharm. Res. 2005, 22 (11), 1821-1828.
25. Radomski, A.; Jurasz, P.; Alonso-Escolano, D.; Drews, M.; Morandi, M.; Malinski, T.; Radomski, M. W. Nanoparticle-induced platelet aggregation and vascular thrombosis. Br. J. Pharmacol. 2005, 146 (6), 882-893.
26. Knopf, P. M.; Rivera, D. S.; Hai, S. H.; McMurry, J.; Martin, W.; De Groot, A. S. Novel function of complement C3d as an autologous helper T-cell target. Immunol. Cell Biol., in press.
27. Chanan-Khan, A.; Szebeni, J.; Savay, S.; Liebes, L.; Rafique, N. M.; Alving, C. R.; Muggia, F. M. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann. Oncol. 2003, 14 (9), 1430-1437.
28. Reddy, S. T.; van der Vlies, A. J.; Simeoni, E.; Angeli, V.; Randolph, G. J.; O'Neil, C. P.; Lee, L. K.; Swartz, M. A.; Hubbell, J. A. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat. Biotechnol. 2007, 25 (10), 1159-1164.
29. Vonarbourg, A.; Passirani, C.; Saulnier, P.; Simard, P.; Leroux, J. C.; Benoit, J. P. Evaluation of pegylated lipid nanocapsules versus complement system activation and macrophage uptake. J. Biomed. Mater. Res. A 2006, 78 (3), 620-628.
30. Bartlett, D. W.; Davis, M. E. Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles. Bioconjugate Chem. 2007, 18 (2), 456-468.
31. Nagayama, S.; Ogawara, K.; Fukuoka, Y.; Higaki, K.; Kimura, T. Time-dependent changes in opsonin amount associated on nanoparticles alter their hepatic uptake characteristics. Int. J. Pharm. 2007, 342 (1-2), 215-221.
32. Al-Hanbali, O.; Rutt, K. J.; Sarker, D. K.; Hunter, A. C.; Moghimi, S. M. Concentration dependent structural ordering of poloxamine 908 on polystyrene nanoparticles and their modulatory role on complement consumption. J. Nanosci. Nanotechnol. 2006, 6 (9-10), 3126-3133.
33. Bertholon, I.; Vauthier, C.; Labarre, D. Complement activation by core-shell poly(isobutylcyanoacrylate)-polysaccharide nanoparticles: influences of surface morphology, length, and type of polysaccharide. Pharm. Res. 2006, 23 (6), 1313-1323.
34. Fang, C.; Shi, B.; Pei, Y. Y.; Hong, M. H.; Wu, J.; Chen, H. Z. In vivo tumor targeting of tumor necrosis factor-alpha-loaded stealth nanoparticles: effect of MePEG molecular weight and particle size. Eur. J. Pharm. Sci. 2006, 27 (1), 27-36.
35. Zahr, A. S.; Davis, C. A.; Pishko, M. V. Macrophage uptake of core-shell nanoparticles surface modified with poly(ethylene glycol). Langmuir 2006, 22 (19), 8178-8185.
36. Cui, Z.; Mumper, R. J. Coating of cationized protein on engineered nanoparticles results in enhanced immune responses. Int. J. Pharm. 2002, 238 (1-2), 229-239.
37. Cuna, M.; Alonso-Sandel, M.; Remunan-Lopez, C.; Pivel, J. P.; Alonso-Lebrero, J. L.; Alonso, M. J. Development of phosphorylated glucomannan-coated chitosan nanoparticles as nanocarriers for protein delivery. J. Nanosci. Nanotechnol. 2006, 6 (9-10), 2887-2895.
38. Csaba, N.; Sanchez, A.; Alonso, M. J. PLGA:poloxamer and PLGA:poloxamine blend nanostructures as carders for nasal gene delivery. J. Controlled Release 2006, 113 (2), 164-172.
39. Goppert, T. M.; Muller, R. H. Protein adsorption patterns on poloxamer- and poloxamine-stabilized solid lipid nanoparticles (SLN). Eur. J. Pharm. Biopharm. 2005, 60 (3), 361-372.
40. Muller, R. H.; Maassen, S.; Weyhers, H.; Mehnert, W. Phagocytic uptake and cytotoxicity of solid lipid nanoparticles (SLN) sterically stabilized with poloxamine 908 and poloxamer 407. J. Drug Targeting 1996, 4 (3), 161-170.
41. Paciotti, G. F.; Myer, L.; Weinreieh, D.; Goia, D.; Pavel, N.; McLaughlin, R. E.; Tamarkin, L. Colloidal gold: a novel nanoparticle vector for tumor directed drug delivery. Drug Delivery 2004, 11 (3), 169-183.
42. Redhead, H. M.; Davis, S. S.; Illum, L. Drug delivery in poly(lactide-co-glycolide) nanoparticles surface modified with poloxamer 407 and poloxamine 908: in vitro characterisation and in vivo evaluation. J. Controlled Release 2001, 70 (3), 353-363.
43. Owens, D. E., 3rd; Peppas, N. A. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int. J. Pharm. 2006, 307 (1), 93-102.
44. Frank, M. M.; Fries, L. F. The role of complement in inflammation and phagocytosis. Immunol. Today 1991, 12 (9), 322-326.
45. Lynch, I.; Cedervall, T., Lundqvist, M.; Cabaleiro-Lago, C.; Linse, S.; Dawson, K. A. The nanoparticle-protein complex as a biological entity; a complex fluids and surface science challenge for the 21st century. Adv. Colloid Interface Sci. 2007 134-135, 167-174.
46. Chellat, F.; Grandjean-Laquerdere, A.; Le Naour, R.; Fernandes, J.; Yahia, L.; Guenounou, M.; Laurent-Maquin, D. Metalloproteinase and cytokine production by THP-1 macrophages following exposure to chitosan-DNA nanoparticles. Biomaterials 2005, 26 (9), 961-970.
47. Ljubimova, J. Y.; Fujita, M.; Khazenzon, N. M.; Lee, B. S.; Wachsmann-Hogiu, S.; Farkas, D. L.; Black, K. L.; Holler, E. Nanoconjugate based on polymalic acid for tumor targeting. Chem. Biol. Interact. 2008, 171 (2), 195-203.
48. Niidome, T.; Yamagata, M.; Okamoto, Y.; Akiyama, Y.; Takahashi, H.; Kawano, T.; Katayama, Y.; Niidome, Y. PEG-modified gold nanorods with a stealth character for in vivo applications. J. Controlled Release 2006, 114 (3), 343-347.
49. Hall, J. B.; Dobrovolskaia, M. A.; Patri, A. K.; McNeil, S. E. Characterization of nanoparticles for therapeutics. Nanomedicine 2007, 2 (6), 789-803.
50. Standard Test Method for Analysis of Hemolytic Properties of Nanoparticles. ASTM International: 2008; E2524-08.
51. Standard Test Method for Evaluation of the Effect of Nanoparticulate Materials on the Formation of Mouse Granulocyte-Macrophage Colonies. ASTM International: 2008; E2525-08.
52. http://www.iso.org/iso/standards_development/technical_committees/ list_of_iso_technical_committees/iso_technical_committee.htm?commid= 381983.